Brief Summary

Bacterial vaginosis is a syndrome manifested by adverse alterations in vaginal microbial flora. It is present in 10 to 25% of women in the general population, and is the most common vaginal infection. It has been associated with a number of adverse sequelae in reproductive health including acquisition of HIV, pelvic inflammatory disease, cervical dysplasia, and complications of gynecological procedures. During pregnancy it has been associated with an increased risk of preterm birth an postpartum maternal infection. However, the vaginal microbial flora remains poorly understood. Information on variation in microbial flora and its association with BV from a longitudinal study is unavailable. This prospective observational study aims to advance our knowledge of the natural history and abnormal alteration in vaginal microbial flora, and to identify risk factors that are associated with these changes. A total of 5500 healthy, non-pregnant women of reproductive age will be enrolled and followed up in Birmingham, Alabama, for one year (baseline visit plus once every three months afterwards, totaling 5 visits). Detailed information on sociodemographic status, medical history, hygiene practice, sexual behavior and psychosocial stress will be collected through in-person interviews. Routine gynecological and dental examinations will be carried out during the study visits. Samples of vaginal secretion and blood will be collected. Laboratory tests to quantify vaginal microbial flora and to identify infection of bacterial vaginosis as well as common sexually transmitted diseases will be conducted. This project is expected to complete in 5 years.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 1999

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 14, 1999

Completed
7.2 years until next milestone

First Submitted

Initial submission to the registry

June 19, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 21, 2006

Completed
4.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 18, 2010

Completed
Last Updated

July 2, 2017

Status Verified

November 18, 2010

First QC Date

June 19, 2006

Last Update Submit

June 30, 2017

Conditions

Keywords

Bacterial VaginosisVaginal InfectionVaginitisCohort StudySexually Transmitted Disease

Eligibility Criteria

Age15 Years - 44 Years
Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may not qualify if:

  • Immunocompromised status
  • Receiving or expected to receive in the next 12 months cytotoxic or immunosuppressive drugs.
  • Receiving or expected to receive in the next 12 months one or more 30-day courses of corticosteroids.
  • Congenital or acquired immune deficiency; known HIV positivity.
  • Primary or secondary affective disorder, psychosis, emotional or intellectual limitations that preclude informed consent.
  • Non-fluency in English.
  • Post-menopausal (natural or surgical).
  • Status post hysterectomy or expected to undergo hysterectomy in the next 12 months.
  • Status post pelvic radiotherapy, or expected to undergo pelvic radiotherapy in the next 12 months.
  • Receiving or expected to receive chronic (daily for at least 30 days) antibiotics in the next 12 months.
  • Planning to move out of the area in the next 12 months.
  • Participating or expected to participate during the next 12 months in a clinical trial in which antibiotics or topical microbicides will be administered in a blinded manner.
  • Women who unexpectedly develop one of these conditions during their participation will continue to be followed, unless a specific contraindication arises.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Alabama

Birmingham, Alabama, United States

Location

Related Publications (3)

  • Goldenberg RL, Klebanoff MA, Nugent R, Krohn MA, Hillier S, Andrews WW. Bacterial colonization of the vagina during pregnancy in four ethnic groups. Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol. 1996 May;174(5):1618-21. doi: 10.1016/s0002-9378(96)70617-8.

    PMID: 9065140BACKGROUND
  • Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983 Jan;74(1):14-22. doi: 10.1016/0002-9343(83)91112-9.

    PMID: 6600371BACKGROUND
  • Fanchin R, Harmas A, Benaoudia F, Lundkvist U, Olivennes F, Frydman R. Microbial flora of the cervix assessed at the time of embryo transfer adversely affects in vitro fertilization outcome. Fertil Steril. 1998 Nov;70(5):866-70. doi: 10.1016/s0015-0282(98)00277-5.

    PMID: 9806568BACKGROUND

MeSH Terms

Conditions

Vaginosis, BacterialVaginitisSexually Transmitted Diseases

Condition Hierarchy (Ancestors)

Bacterial InfectionsBacterial Infections and MycosesInfectionsVaginal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesCommunicable DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Sponsor Type
NIH

Study Record Dates

First Submitted

June 19, 2006

First Posted

June 21, 2006

Study Start

April 14, 1999

Study Completion

November 18, 2010

Last Updated

July 2, 2017

Record last verified: 2010-11-18

Locations